311 related articles for article (PubMed ID: 36933003)
1. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
[TBL] [Abstract][Full Text] [Related]
2. Fetal-origin cells in maternal circulation correlate with placental dysfunction, fetal sex, and severe hypertension during pregnancy.
Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
J Reprod Immunol; 2024 Mar; 162():104206. PubMed ID: 38309014
[TBL] [Abstract][Full Text] [Related]
3. Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies.
Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
J Reprod Immunol; 2023 Sep; 159():104114. PubMed ID: 37473584
[TBL] [Abstract][Full Text] [Related]
4. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
5. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
[TBL] [Abstract][Full Text] [Related]
6. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies.
Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381
[TBL] [Abstract][Full Text] [Related]
7. Alterations in maternal sFlt-1 and PlGF: Time to labor onset in term-/late-term pregnancies with and without placental dysfunction.
Mitlid-Mork B; Bowe S; Staff AC; Sugulle M
Pregnancy Hypertens; 2022 Dec; 30():148-153. PubMed ID: 36228400
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
[TBL] [Abstract][Full Text] [Related]
9. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
[TBL] [Abstract][Full Text] [Related]
10. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble fms-like tyrosine kinase-1 binding or diminished production of placental growth factor?
Kluivers ACM; Biesbroek A; Visser W; Saleh L; Russcher H; Danser AHJ; Neuman RI
Ultrasound Obstet Gynecol; 2023 Apr; 61(4):466-473. PubMed ID: 36191149
[TBL] [Abstract][Full Text] [Related]
12. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
13. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL
Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175
[TBL] [Abstract][Full Text] [Related]
14. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
[TBL] [Abstract][Full Text] [Related]
15. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
[TBL] [Abstract][Full Text] [Related]
16. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
[TBL] [Abstract][Full Text] [Related]
17. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.
Park HJ; Kim SH; Jung YW; Shim SS; Kim JY; Cho YK; Farina A; Zanello M; Lee KJ; Cha DH
BMC Pregnancy Childbirth; 2014 Jan; 14():35. PubMed ID: 24444293
[TBL] [Abstract][Full Text] [Related]
18. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
[TBL] [Abstract][Full Text] [Related]
19. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
Aggarwal PK; Chandel N; Jain V; Jha V
J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women.
Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S
J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
